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The melanoma cell adhesion molecule was identified adhesion molecule promoter activity was impeded
upon treatment with phorbol esters or in the presenceas a human melanoma-associated antigen that
increases in expression as tumors increase in thickness of stem cell factor, a phenomenon which was protein
kinase C-dependent. Promoter-deletion studies dem-and begin to acquire metastatic potential. Clinical and
experimental evidences suggest that the development onstrated that the first 196 nt of the melanoma cell
adhesion molecule promoter region are sufficient toof metastatic capacity might be the consequence
of increased melanoma cell adhesion molecule get full expression in metastatic melanoma cells. This
fragment contains five binding sites for the transcrip-expression. The mechanisms for upregulation of the
melanoma cell adhesion molecule during melanoma tion factor Sp1 and DNA mobility shift experiments
showed direct binding of Sp1 to the promoter. Inprogression are, however, still poorly understood. In
this study, we show that melanoma cell adhesion conclusion, our results indicate that Sp1 is sufficient
to drive constitutive melanoma cell adhesion moleculemolecule expression is tightly regulated at the
transcriptional level. Using a combination of CAT expression in metastatic melanoma cells. In nonmeta-
static cells, however, melanoma cell adhesion moleculereporter assays and semiquantitative reverse tran-
scriptase–polymerase chain reaction, we observed that expression is repressed and we speculate that stem cell
factor/c-Kit signaling might be responsible for thecyclic adenosine monophosphate significantly
increases transcription of the melanoma cell adhesion control of melanoma cell adhesion molecule synthesis,
and thus, perhaps, of melanoma progression andmolecule in nonmetastatic melanoma cells. In meta-
static cells, transcription of the gene was constitutive metastasis. Key words: melanoma/melanoma cell adhesion
molecule/Sp1/stem cell factor/c-Kit. J Invest Dermatoland could not be further increased by cyclic adenosine
monophosphate. On the other hand, melanoma cell 113:711–719, 1999
M but at lower levels than on primary or metastatic melanoma (Shihet al, 1994a). The expression of MCAM by human melanoma celllines correlates with their ability to grow and produce metastasesin nude mice (Luca et al, 1993). Moreover, enforced expressionof MCAM in low-tumorigenic, nonmetastatic melanoma cellsalignant melanomas are invasive and highly meta-static tumors which arise from dendritic pig-mented melanocytes (Mancianti and Herlyn,1989). The cell surface glycoprotein melanomacell adhesion molecule (MCAM) (previously
known as MUC18, Mel-cam, or CD146) was identified as a human significantly increases their tumorigenicity and metastatic potential
melanoma-associated antigen that increases in expression as tumors in nude mice (Xie et al, 1997a) and the production of tumorigenic
increase in vertical thickness and begin to acquire metastatic variants from a nontumorigenic melanoma cell line is accompanied
potential (Lehmann et al, 1987). No expression of MCAM antigen by MCAM upregulation (Bani et al, 1996). Finally, transfection of
has been detected in normal melanocytes, normal adult skin, or AP-2 regulatory factors into highly metastasic melanoma cells
skin adjacent to melanocytic lesions (Shih et al, 1994a, b; Kraus inhibits their tumor growth and metastatic potential in nude mice
et al, 1997). MCAM antigen, however, can be detected on nevi, through downregulation of MCAM expression (Jean et al, 1998a).
These various lines of evidence support the hypothesis that the
development of metastatic capacity in melanoma may result from
increased MCAM expression.
Manuscript received February 9, 1999; revised June 14, 1999; accepted The mechanisms for upregulation of MCAM expression during
for publication July 22, 1999. melanoma progression are unknown. There is no evidence that
Reprint requests to: Dr. Ste´phane Karlen, Dermatological Clinic, Insel- the expression of MCAM by malignant tumors is associated eitherspital, CH-3010 Bern, Switzerland. Email: stephane.karlen@insel.ch
with chromosomal translocation, mutation, or gene amplificationAbbreviations: CAT, chloramphenicol acetyltransferase; CRE, cAMP
(Luca et al, 1993). MCAM expression is essentially restricted toresponse element; CREB, cAMP response element binding protein;
tumors of the neuroectodermal lineage and in cutaneous melanomaGAPDH, glyceraldehyde-3-phosphate-dihydrogenase; MCAM, melanoma
cell adhesion molecule; SCF, stem cell factor. it appears to increase with tumor thickness and progression. These
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Plasmid construct To generate the MCAM promoter CAT constructtwo observations indicate that the regulation of MCAM synthesis
(pMCAM-IV-CAT; Fig 1), the following strategy was used. The 59-is transcriptional (Grimm and Johnson, 1995). An increase in
flanking region of the MCAM gene (nt 15 to –527) was amplified byintracellular cyclic adenosine monophosphate (cAMP) levels leads
PCR, using the Clontech Advantage-GC genomic PCR system (Paloto an upregulation of cell surface MCAM due to increased mRNA
Alto, CA). The RNA initiation site was designated 11. The PCR productsynthesis (Rummel et al, 1996). In contrast, exposure of the cells was subcloned upstream of the CAT gene into the pCAT3 basic vector
to phorbol esters reduces expression to background levels by 24 h. (Promega, Madison, WI) by using the SacI and BglII sites. The sequence
This downregulation is associated with a significant decrease in of the promoter was verified by sequencing. The construct pMCAM-III-
mRNA levels. These later observations point to a protein kinase CAT was obtained by cutting pMCAM-IV-CAT at the SacI site (site in
the polylinker) and TthIII1 (nt –392), filling the ends with T4 DNA, andC (PKC)-activated pathway that could repress MCAM expression.
religating. Similarly, pMCAM-II-CAT, pMCAM-I-CAT and pMCAM-0-In malignant tumors this pathway would be no longer functional.
CAT were made by cutting the pMCAM-IV-CAT construct at the SacIThe proto-oncogene c-Kit encodes a transmembrane tyrosine-
site and the BstXI (nt –195), SrfI (nt –65), or XhoI (nt –11), respectively,protein kinase receptor. Whereas normal function of c-Kit is
making the ends blunt and religating. pMCAM-del1-CAT, pMCAM-del2-required for human melanocyte development, its expression CAT, and pMCAM-del3-CAT were obtained by removing from pMCAM-
progressively decreases during local tumor growth and invasion of IV-CAT the AatII–XhoI fragment (nt –11 to –30) the BssHII–AatII fragment
human melanoma (Lassam and Bickford, 1992; Natali et al, 1992). (nt –26 to –105) and the NarI–AatII fragment (nt –26 to –134), respectively.
The ligand for c-Kit, stem cell factor (SCF), has a growth inhibitory Finally, pMCAM-del4-CAT was made by cutting pMCAM-IV-CAT with
effect on c-Kit expressing melanoma cells (Funasaka et al, 1992; XhoI (nt –11) and BglII (site in the polylinker), filling the ends and
religating. The pSV-βGal vector was purchased from Promega.Zakut et al, 1993) by inducing apoptosis (Huang et al, 1996). As
SCF has been shown to be a regulator of PKC activity
Transient transfections and CAT assays Melanoma cells (8 3 105)(Blume-Jensen et al, 1993, 1995), it seems possible that MCAM
were transfected with 2.5 µg of the various MCAM CAT constructs andexpression may be controlled by signaling through the c-Kit
0.5 µg of pSV-βGal DNA with Fugene6 reagent (Roche Diagnostics).receptor.
Two hours post-transfection, PMA, forskolin, and SCF were added, eitherSequence analysis on the MCAM promoter region reveals several
alone or in various combinations, and the cells were incubated further forinteresting properties (Sers et al, 1993). The 150 bp fragment found 22 h at 37°C. The cells were then washed with phosphate-buffered saline
immediately upstream of the transcription site is 88% (G 1 C)- (PBS) and harvested in 1 3 Reporter Lysis Buffer (Promega). MCAM
rich. No TATA or CAAT boxes can be identified, but the promoter activity was determined by measuring CAT activity. One hundred
pyrimidine-rich initiator sequence (Inr) CTCACTT (Smale and and twenty-five microliters of cell extract (preheated for 10 min at 60°C)
were incubated for 3 h at 37°C in the presence of 5 µg per ml of n-Butyril-Baltimore, 1989) is found overlapping the RNA start site. Five
CoA and 150 µCi of D-threo-[dichloroacetyl-1-14C] chloramphenicolGC boxes which bind the transcription factor Sp1 (Dynan and
(Amersham). CAT activities were visualized by thin layer chromatographyTjian, 1983) are clustered within 130 bp from the Inr. The MCAM
assay or quantitated by liquid scintillation counting (LSC assay). Normaliza-promoter also contains four putative AP-2 binding elements. AP-
tion of transfection efficiency was done using a cotransfected pSV-βGal2 plays an important part in the control of gene expression in vector and measuring β-galactosidase activity. The efficiency of transfection
melanomas. Upregulation of MCAM (Jean et al, 1998a) and in SB2 cells was 20 times lower than in SK-Mel2 cells. Fold activation or
downregulation of c-Kit expression (Huang et al, 1998) in highly inhibition of CAT activity were calculated relative to control cells which
metastatic cells correlate with loss of expression of the transcription were given the reference value of 100. Results are the mean of three
factor AP-2. A consensus motif for the cAMP-response element independent experiments. Error bars represent SEM.
(CRE) is found at position –32 in the control region. The CRE-
binding factor, CREB, has been recently found to be involved in RNA analysis Total RNA was extracted from 106 cells using the SV
total RNA isolation system from Promega. Detection of MCAM, c-Kit,the malignant transformation of melanoma cells (Jean et al, 1998b).
and GAPDH mRNA was performed using the one tube/two enzymesAs mentioned above, MCAM expression can be modulated by
Access reverse transcriptase–PCR system developed by Promega and 100 ngcAMP, thus this particular CRE motif could account for MCAM
of total RNA for standard reactions. The following oligonucleotides wereupregulation in response to cAMP-inducing agents.
used as primers. MCAM sense: (nt 185–206) 59-CCAAGGCAACCTCAG-In this study, we developed a transient transfection assay for CCATGTC-39; MCAM anti-sense (nt 598–622) 59-CTCGACTCCACA-
measuring the activity of MCAM-CAT reporter gene constructs GTCTGGGACGACT-39. c-Kit sense (nt 1326–1347) 59-GCC-
in human melanoma cells. We demonstrated that MCAM expression CACAATAGATTGGTATTT-39; c-Kit anti-sense (nt 1875–1896) 59-
is tightly regulated at the transcriptional level. We also provide AGCATCTTTACAGCGACAGTC-39. GAPDH sense (nt 85–106) 59-
AACGGATTTGGTCGTATTGGGC-39 and anti-sense (nt 663–684) 59-evidence that MCAM mRNA synthesis can be downregulated
AGGGATGATGTTCTGGAGAGCC-39. PCR products were analyzedthrough activation of the SCF/c-Kit regulatory pathway.
by electrophoresis on 2% agarose gels and visualized by ethidium bromide
staining. For semiquantitative reverse transcriptase–PCR analysis of MCAMMATERIALS AND METHODS
mRNA, we used the following strategy (Yawalkar et al, 1998). A 1:4 serial
dilution from each RNA extraction was prepared, with the concentrationCell lines and culture conditions The human melanoma cell line
of the first sample being set to 100 ng per µl. An aliquot from each dilutionSK-Mel2 was purchased from ATCC (catalog no. HTB68) and is highly
was then subjected to 32 cycles of PCR amplification (20 s at 95°C, 20 smetastatic in nude mice (Fogh et al, 1977). The SB2 cell line was isolated
at 52°C and 30 s at 72°C in a Perkin Elmer 9600 thermocycler) with thefrom a primary cutaneous lesion and was a gift from Dr B. Giovanella
appropriate primers. The resulting products were analyzed as described(The Stehlin Foundation for Cancer Research, Houston, TX). In nude mice
above. The exposed films obtained from the gels were evaluated with anthe SB2 cell line is poorly tumorigenic and nonmetastatic (Verschraegen et al,
optometric scanner and the integrated optical density in arbitrary units of1991; Luca et al, 1993; Singh et al, 1995).
each amplified fragment was determined. The dilution at which a 50%The SK-Mel2 cell line was maintained in culture as adherent monolayers
reduction of the signal was obtained is determined for both the MCAMin Earle’s minimal essential medium supplemented with 10% fetal bovine
and the GAPDH messengers. The amounts of MCAM transcripts, relativeserum, sodium pyruvate, nonessential amino acids, 2-fold vitamin solution,
to the GAPDH control, was calculated and the results were expressed asand penicillin–streptomycin (Gibco-Life Technologies, Basel, Switzerland).
the relative amount of mRNA. Results are the mean of three independentThe SB2 cells were maintained in MCDB153 medium (Sigma, St Louis,
experiments. Error bars represent SEM.MO) supplemented with LB15 medium (four parts MCDB and one part
LB15), 2% fetal bovine serum, L-glutamine, and penicillin–streptomycin.
For stimulation studies, phorbol 12-myristate 13-acetate (PMA) and forsko- DNA mobility shift experiments Melanoma nuclear cell extracts were
lin (both purchased from Sigma) were used at concentrations of 10 ng per obtained from a small number of cells (107) using the method described
ml and 20 µM, respectively. The human recombinant SCF was obtained by Schreiber et al (1993) with the following modifications: Complete
from Roche Diagnostics (Basel, Switzerland) and was used at a final Protease Inhibitor Cocktail solution (Roche Diagnostics), specific for
concentration of 50 ng per ml. The cAMP-dependent protein kinase serine, cysteine, and metalloproteases, was added to the reaction buffers
inhibitor H89 and the PKC inhibitor GF109203X were purchased from just before lysis. Nuclear protein extracts were assayed for protein content
by the BioRad (BioRad Laboratories, Hercules, CA) protein assay reagentCalbiochem (La Jolla, CA) and used at a concentration of 5 µM.
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Figure 1. A diagrammatic representation of the
MCAM promoter region. The RNA initiation site
(arrow) was designated 11. Regulatory elements which
have been previously described and which are
potentially involved in the expression of the gene
(Sers et al, 1993) are indicated. Promoter/deletion
constructs used in the study are shown.
kit. Standard binding reaction contained 2.5 µg of nuclear protein, 60 mM synthesis was maintained even when cells were costimulated with
KCl, 8 mM MgCl2, 12 mM HEPES buffer pH 7.9, 12% glycerol, 1 mM forskolin. Figure 3(b) demonstrates that PMA acted at the transcrip-
dithiothreitol, 3 µg poly(dI–dC), and 25 fmol end-labeled oligonucleotide tional level. Indeed, the activity shown by the MCAM promoter
probe. The binding reactions were left on ice for 20 min. Protein/DNA in unstimulated or forskolin-treated cells was greatly reduced when
complexes were resolved at 4°C on a 5% nondenaturing polyacrylamide the cells were costimulated with PMA.gel. The gels were dried and exposed to a phosphoimager screen and
analyzed with the Storm 860 instrument (Molecular Dynamics, Sunnyvale, MCAM expression in SB2-cells To confirm that MCAMCA). For competition assays, unlabeled oligonucleotides were added 20 min
expression is regulated at the transcriptional level, the activity ofbefore adding the probe. The SCA probe was a 35 bp oligonucleotide
pMCAM-IV-CAT was analyzed in the nonmetastatic MCAMwhich covers the MCAM promoter region from position –12 to –46 and
negative SB2 melanoma cells (Fig 4). Very low to undetectableincludes the Sp1 site at nt –41, the CRE site at nt –32, and the AP-2 site
at position –24. The 23 bp ASP probe covers the promoter sequence from CAT activity could be observed in unstimulated SB2 cells (Fig 4a).
nt –113 to –135 and contains the AP-2 site at position –130 and the Sp1 In contrast to that observed with SK-Mel2 cells, the MCAM
site at position –124. Competitor oligonucleotides with high-affinity promoter reacted strongly to forskolin treatment, demonstrating
binding sequences for either Sp1, CREB/ATF, or AP-2 were purchased that the MCAM promoter can respond to cAMP elevation. MCAM
from Santa-Cruz Biotechnology (Santa Cruz, CA). The mutated SCA transcriptional activities in stimulated SB2 cells, however, were still
oligonucleotides used in competition studies are described in Fig 9 and significantly lower than in the metastatic SK-Mel2 cells. MCAMthe mutated ASP oligonucleotides are shown in Fig 8. Unless otherwise
mRNA synthesis was hardly detectable in the nonmetastatic SB2stated, the oligonucleotides were synthesized by Microsynth (Balgach,
cells when compared with the abundant production of MCAMSwitzerland). Anti-Sp1, CREB/AT-1, ATF-2 and AP-2 antibodies (Santa-
transcripts observed in the SK-Mel2 cell line (Fig 4b). UponCruz) were used in supershift analyses as previously described by Karlen
et al (1996). forskolin treatment, however, the amounts of MCAM mRNA
produced by the two cell lines were comparable (Fig 4c).
RESULTS The effects of forskolin could be strongly attenuated in the
presence of H89, a specific inhibitor of cAMP-dependent proteinMCAM promoter activity in melanoma cells In an attempt
kinases (Song et al, 1998) (Fig 5a). Similarly, the production ofto elucidate further the molecular mechanisms controlling MCAM
MCAM transcripts was severely impaired by PMA at inductiontranscription, the activity of the CAT reporter gene driven by the
with forskolin. The blocking effect of PMA, however, was releasedMCAM promoter (nt 15 to –527; Fig 1) was analyzed in the
upon addition of GF109203X, a specific inhibitor of PKC (Songhighly metastatic SK-Mel2 melanoma cell line. The results are
et al, 1998). Interestingly, SCF, the ligand for the c-Kit receptor,summarized in Fig 2(a, b). MCAM promoter activity was strong
had a similar effect to PMA on MCAM RNA synthesis in c-Kitin unstimulated SK-Mel2 cells (Fig 2b, lane 1). Upon treatment
positive SB2 cells treated with forskolin (Fig 5a, b). Like in thewith forskolin (a potent activator of adenylate cyclase and, therefore,
PMA costimulation studies, the block was released upon additionof cAMP), however, MCAM promoter activity was only marginally
of GF109203X. SCF had no effect on MCAM transcription in theincreased (lane 2). The high level of MCAM promoter activity in
c-Kit negative SK-Mel2 cell line and expression of c-Kit was notunstimulated cells was not surprising. Like the majority of the
induced in those cells after treatment with forskolin (data notmelanoma cell lines, SK-Mel2 is tumorigenic and metastatic in
shown). Taken together, these data suggest that MCAM expressionnude mice (Fogh et al, 1977) and consequently might be expected
may be controlled by alternative antagonist stimulatory pathways.to express a high amount of MCAM mRNA. Indeed, and as
demonstrated in a semiquantitative reverse transcriptase–PCR assay
Deletion analysis of the MCAM promoter region The(Fig 2c, d), MCAM transcripts were highly expressed in unstimu-
MCAM promoter fragment used in the transfection experimentslated SK-Mel2 cells. Similarly, MCAM mRNA synthesis could
appears to harbor sufficient genetic information to drive constitutiveonly be slightly increased in the presence of forskolin. These data
expression in highly metastatic melanoma cells. We were thereforeindicate that MCAM production in SK-Mel2 cells is constitutive
interested to identify the regulatory elements required for constitu-and that the high level of MCAM expression is the consequence
tive MCAM expression. This fragment contains, in particular, fourof increased transcriptional activity.
sequence motifs at position –24, –130, –410, and –505 identical
to the core region of an AP-2 binding element (Fig 1). Five GCDownregulation of MCAM promoter activity by phorbol
esters Previous experiments by Rummel et al (1996) indicated boxes, at position –41, –72, –77, –99, and –124, respectively, with
a binding site for the transcription factor Sp1 have been mappedthat MCAM mRNA levels were reduced in melanoma cells
treated with PMA. Similarly, we observed a significant decrease in within 130 bp upstream of the RNA initiation site. A consensus
sequence motif for the cAMP-response element CRE was foundendogenous MCAM transcripts in SK-Mel2 cells in the presence
of PMA (Fig 3a). The block imposed by PMA on MCAM mRNA at position –32. To assess the role played by these putative cis-
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Figure 2. Activity of the MCAM promoter is
constitutive in metastatic melanoma cells. (A, B)
CAT activities expressed from the MCAM promoter
region. SK-Mel2 cells were transfected with 2.5 µg of
CAT constructs and 0.5 µg of pSVβGal in the absence
(–) or in the presence (1) of 20 µM forskolin (F). CAT
assays were carried out 24 h later and analyzed by thin
layer chromatography (A) or LSC (B). In the LSC assay,
results are expressed relative to the activity found in
cells transfected with the pMCAM-IV-CAT DNA and
are normalized for transfection efficiency. Data are
mean 6 SEM of three experiments in duplicates. (C)
Access reverse transcriptase–PCR analysis of MCAM
expression. MCAM transcripts were specifically
amplified from unstimulated (–F) or forskolin-treated
(1F) SK-Mel2 cells. Standard reactions contained
100 ng of total RNA (or where indicated 10, 1, and
0.1 ng). After 32 cycles of amplification, the products
were analyzed by electrophoresis on 2% agarose and
stained with ethidium bromide. The arrow shows the
438 bp MCAM product. (D) Semiquantitative reverse
transcriptase–PCR analysis. Amplified products of
MCAM were electrophoresed on 2% agarose,
visualized with ethidium bromide, and analyzed by
densitometric scanner. Semiquantitative analysis was
performed using the levels of GAPDH transcripts as
internal reference. Y-axes show the relative amount
of MCAM mRNA in percentage of GAPDH. Scale:
mean 6 SEM.
acting element in MCAM transcription, the promoter region was ized by a significant decrease in MCAM promoter function. Finally
the deletion in pMCAM-del4 of the Inr element, which overlapsdivided in four ‘‘so-called’’ control domains. Domain I contains
the RNA initiation site and the Sp1/CRE/AP-2 binding site the RNA start site, led to almost a complete loss in MCAM
promoter activity. The transcriptional activity of the three internalcluster around position –32 (SCA box). Domain II extends from
position –66 to –196 and is characterized by the presence of three deletion constructs (pMCAM-del1, -del2, and -del3; Fig 7) was
markedly reduced in the presence of PMA. As for the 59-deletionSp1 sites and by the Asp box, an hybrid element made of the Sp1
element found at position –124 partially overlapped by the AP-2 constructs, the promoter activities of the internal mutants in
forskolin-treated cells were proportionally similar to those obtainedbinding element located at position –130. Finally, domain III (nt –
196 to –391) harbors a putative c-Myb regulatory element and in SK-Mel2 cells (data not shown).
domain IV (nt –391 to –527) contains two additional AP-2 binding
Binding to the ASp element In the MCAM promoter, thesites. Deletion constructs were produced in which those domains
region extending from –118 to –130 is characterized by the presencewere removed sequentially, transfected in SK-Mel2 and CAT
of the ASp box. This sequence was found to be critical for MCAMactivity was measured (Fig 6a). The deletion of domains IV and III
promoter activity (Fig 7). Probably due to the high GC content(constructs pMCAM-III-CAT and pMCAM-II-CAT, respectively)
of the MCAM proximal promoter region, we were unable to usedid not significantly affect MCAM promoter activity. Removal of
site-directed mutagenesis to assess the specific contribution of eachdomain II, which eliminated the ASp cluster and the majority of
of the components of the ASp element. Thus, DNA mobility shiftthe Sp1 sites, reduced promoter activity to around 30% of that
experiments with extracts from SK-Mel2 cells were performed inobtained with the full length construct. Finally, upon removal of
order to identify factors binding to that region. A 23 bp oligo-domain I (construct pMCAM-0-CAT), which contains the SCA
nucleotide, which covers the MCAM promoter region fromelement, promoter activity was reduced to background levels. The
position –113 to –135 and includes the ASp element, was used inactivity of all the deletion constructs was significantly reduced in
the assay. The formation of a major DNA/protein complex couldcells treated with PMA. The MCAM 59-deletion constructs
be observed (Fig 8a). Binding appeared to be specific for the ASpdescribed above were then tested in SB2 cells (Fig 6b). In
box, because it could be efficiently inhibited with an excess of ASpunstimulated cells, low or no activity could be detected. In forskolin-
oligonucleotide, but not with a similar excess of AP-1 bindingtreated cells, however, the promoter activities were proportionally
sequence. The binding pattern was identical with extracts fromsimilar to the activities observed in unstimulated SK-Mel2 cells.
SK-Mel2 and SB2 cells, treated or not with PMA or forskolinAddition of PMA resulted in a marked decrease in CAT production.
(data not shown).The activation of a cAMP-dependent/PMA-sensitive pathway
The ASp element has the potential to bind proteins belongingappears therefore to be necessary to get induction of the MCAM
to the AP-2 and Sp1 families of transcription factors. Oligo-gene.
nucleotides with high-affinity sites for AP-2 or Sp1, respectively,These data suggested that most (if not all) cis-acting elements
were used as competitor sequences in the DNA mobility shift assay.required for constitutive MCAM expression are located within
Binding to the ASp element was totally abolished by a 25–125-fold196 nt from the RNA start site. In order to identify those elements,
molar excess of Sp1 binding sequences, whereas a similar excess ofadditional internal deletions were introduced in pMCAM-IV-CAT
AP-2 oligonucleotide had no effect on binding (Fig 8b). Mutations(Fig 7). A similar level of CAT activity was maintained in cells
destroying either the AP-2 or the Sp1 binding motifs weretransfected with pMCAMdel1. In this construct, the deletion (–11
introduced in the MCAM ASp element. These oligonucleotidesto –30) has destroyed the CRE (nt –32) and AP-2 components of
were used in competition experiments. Binding to the ASp elementthe SCA box. A 2-fold increase in MCAM promoter activity was
was severely impaired in the presence of ASp-mut2 oligonucleotidesobserved in cells transfected with pMCAM-del2 (deletion –26 to
(mutation destroying the putative AP-2 binding moiety), but was–105), in which four Sp1 sites and the CRE element were removed.
not affected by an excess of ASp-mut1 sequence (mutation alteringThe further deletion of the AP-2/Sp1 cluster (ASP box) around
position –124 (construct pMCAM-del3) was, however, character- the Sp1 moiety) (Fig 8b). Finally, the formation of the ASp
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Figure 3. PMA downregulates MCAM expression in melanoma
Figure 4. MCAM promoter activity in the nonmetastatic MCAMcells. (A) Semi-quantitative reverse transcriptase–PCR analysis of MCAM
negative SB2 melanoma cell line. (A) Upregulation of MCAM promoterRNA in unstimulated cells (–) or in cells treated either with forskolin (F),
function by forskolin. The pMCAM-IV-CAT construct was transfectedPMA (10 ng per ml), or a combination of the two (F 1 PMA). Assays
into SK-Mel2 or SB2 cells in the presence (1) or in the absence (–) ofwere carried out as described in Fig 2(d) and materials and methods. Y-
forskolin. CAT assays were performed 24 h after transfection and CATaxes show the relative amount of MCAM RNA in percentage of the
activity measured by LSC. Results are expressed relative to the activityGAPDH control. (B) PMA downregulates the activity of the MCAM
found in unstimulated SK-Mel2 cells and normalized for transfectionpromoter. The pMCAM-IV-CAT construct was transfected into SK-Mel2
efficiency. (B) Comparison of MCAM mRNA levels. Total RNA wascells in the presence or not of forskolin (F) and PMA, either alone or in
extracted from SK-Mel2 and SB2 cells and subjected to reverse transcriptase–combination. Cell transfections and CAT assays were performed as described
PCR analysis as described in Fig 2(c). Amplification of GAPDH (600 bp)in Fig 2(a). pMCAM-0-CAT DNA was used as the negative control.
was used as a control for mRNA integrity. (C) MCAM mRNA synthesis
in forskolin-treated cells. MCAM transcripts were analyzed as described
in above.complex could only be altered upon addition of anti-Sp1-specific
antibody (Fig 8c). Taken together, these data indicate that Sp1 is
the unique factor interacting with the ASp box.
oligonucleotide strongly inhibited the formation of the top complex
C1 (Fig 9a). Mutations destroying the Sp1, CRE, and AP-2Binding to the SCA element In the MCAM promoter, the
region extending from –17 to –41 is characterized by the presence binding motifs, either individually or in various combinations, were
introduced in the MCAM SCA element. The resulting mutantsof the SCA box. This element has the potential to bind the Sp1,
CREB/ATF, and AP-2 regulatory factors. Partial destruction of were then used in competition experiment (Fig 9b). Binding to
the SCA box was not affected by an excess of mut1, mut4, mut5,the SCA element resulted in a 2-fold increase in MCAM promoter
activity (Fig 7). In order to identify factors interacting with the and mut7 competing sequences. As Sp1 has been destroyed in
those mutants, these data confirmed the important part played bySCA sequence, a 35 bp oligonucleotide, which covers the MCAM
promoter from position –12 to –46 was used in a DNA mobility this element in MCAM expression. On the opposite, and as
shown in competition studies with the mut2, mut3, and mut6shift assay with extracts from SK-Mel2 cells. The formation of two
DNA/protein specific complexes (C1 and C2) could be observed oligonucleotides, the formation of the C1 and C2 complexes was
completely abrogated by an SCA oligonucleotide containing an(Fig 9a). The binding pattern was similar in PMA or forskolin
stimulated cells, or with extracts from SB2 cells (data not shown). intact Sp1 binding sequence. Finally, only antibodies directed
against the Sp1 factor could affect the formation of the C1 complexBinding to the SCA element was not affected by an excess of CRE
or AP-2 competing sequences, whereas a similar excess of Sp1 in binding experiments (data not shown). Taken together, these
716 KARLEN AND BRAATHEN THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Figure 5. Modulation of MCAM expression
by SCF. (A) PMA and SCF inhibits forskolin-
driven MCAM expression. Semiquantitative
reverse transcriptase–PCR analysis of MCAM
transcripts in SB2 cells treated (where indicated)
with 20 µM forskolin (F), 5 µM H89, 10 ng
per ml PMA, 5 µM GF109203X and 50 ng per
ml SCF. (B) SB2, but not SK-Mel2 expresses c-
Kit, the receptor for SCF. Total RNA (100 ng)
from both cell types was subjected to 32 cycles
of reverse transcriptase–PCR amplification with
primers specific for MCAM (438 bp), c-Kit
(571 bp), and GAPDH (600 bp). Reactions were
carried out as described in Fig 2(c).
an intact Sp1 element. The factor associated to that complex may
account for the 2-fold increase in CAT activity observed upon
partial deletion of the SCA element
DISCUSSION
Although it has been shown that the melanoma cell adhesion
molecule MCAM plays a part in the progression of malignant
melanomas (Xie et al, 1997a; Meier et al, 1998), little is known
about the mechanisms that regulate expression of MCAM in
melanoma cells. cAMP has been involved in the regulation of several
genes in melanocytes and melanomas (Eisen, 1996). Upregulation of
cAMP pathway by forskolin induces melanocyte cell differentiation
characterized by stimulation of melanin synthesis and dendrite
formation (Bertolotto et al, 1998; Busca et al, 1998). MCAM is
not expressed in normal melanocytes (Shih et al, 1994a,b Kraus
et al, 1997) or in the nonmetastatic SB2 cells (Fig 4b; Bar-Eli,
1997). Changes in cAMP intracellular levels, however, markedly
increases expression of the gene (Fig 4c; Rummel et al, 1996). In
contrast, we found that in SK-Mel2 cells expression of the MCAM
gene was constitutive, Sp1-dependent and could not be further
induced by forskolin. Taken together, these observations suggest
that MCAM expression in normal cells may be transcriptionally
repressed. Upon stimulation of a cAMP-dependent pathway, the
block would be released allowing RNA synthesis to take place. In
malignant melanomas, the cells would be in a permanent
de-repressed state, leading to constitutive production of MCAM
RNA.
The strong reactivity of the MCAM promoter to cAMP brings
out a paradoxical situation, i.e., the stimulation of the MCAM
gene in a cell type where it should not be expressed but which
requires cAMP to differentiate fully. A possible explanation to
that paradox would be that MCAM expression is controlled by
alternative stimulatory pathway. Exposure of melanoma cells to
phorbol esters (PMA) reduces MCAM surface expression to back-
ground levels (Rummel et al, 1996). This downregulation isFigure 6. Deletion analysis of the MCAM promoter region. SK-
associated with a significant decrease in mRNA levels that resultsMel2 (A) and SB2 cells (B) were transfected with 2.5 µg of the deletion
from decreased MCAM promoter activity (Figs 3b and 5–7).constructs described in Fig 1, and 0.5 µg of psvβGal. Where indicated the
The effects of forskolin-induced activation and PMA-mediatedcells were treated with PMA, forskolin (F) or a combination of the two
(F 1 PMA). After 24 h, CAT assays were performed and analyzed by downregulation on MCAM synthesis could be blocked by specific
LSC. CAT activity was normalized to β-galactosidase activity and the inhibitors of protein kinase A and PKC, H89 and GF109203X,
results are expressed relative to the activity of pMCAM-IV-CAT. Data are respectively, suggesting that alternative independent regulatory
mean 6SEM of three experiments in duplicates. pathways control expression of the MCAM gene. Opposite effects
of PMA and forskolin treatment have been observed in other gene
systems, especially in the case of cytokine production (Derig et al,results indicate that Sp1 is the main factor involved in the formation
of the C1 complex. They also show that the C2 complex is specific 1990). In the case of interleukin-2, PMA and cAMP elevating
agents were shown to act directly at the transcriptional level byfor the SCA oligonucleotide as none of the competitor could
influence binding, except for the SCA oligonucleotides containing targeting different sets of transcription factors to specific regulatory
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Figure 7. The SCA and ASp elements are
involved in MCAM promoter function. SK-Mel2
cells were transfected with the following constructs:
(i) pMCAM-del1 (deletion of the CRE and AP-2
consensus sites in the SCA box); (ii) pMCAM-del2
(deletion of the Sp1 and CRE motifs in the SCA
element plus removal of three Sp1 putative binding
sites); (iii) pMCAM-del3 (removal of the ASp
element); and (iv) pMCAM-del4 (deletion of the
Inr element overlapping the RNA initiation site).
Experiments were performed as described in Fig 6.
PMCAM-IV-CAT and pMCAM-0-CAT were used
as positive and negative control, respectively.
Figure 8. Binding of Sp1 to the ASp box. DNA
mobility shift experiments were done with nuclear
extracts from SK-Mel2 cells and a 23-mer end-labeled
oligonucleotide (nt –113 to –135) containing the ASp
box. (A) Specific binding to the ASp oligonucleotide.
The probe was incubated either alone (probe) or
with unstimulated (SK2) or forskolin-treated SK-Mel2
(SK2 1 F) extracts. For competition experiments, the
probe was incubated with unstimulated extracts and
unlabeled homologous (ASp) or unrelated (AP-1)
oligonucleotides were added in 25- and 125-fold
excess. (B) Sp1 binds to the ASp box. The ASp probe
was incubated with unstimulated SK-Mel2 nuclear
extracts in the presence of competing
oligonucleotides. For competition, homologous
(ASp), AP-2 and Sp1 consensus and mutated (ASp-
mut1, -mut2, and -mut3) oligonucleotides were added
in 50-fold excess. (C) DNA supershift experiments.
Where indicated, reactions were carried out in the
presence of specific antibody directed against Sp1,
AP-2, and CREB (anti-Sp1, anti-AP-2, and ant-
CREB, respectively). (D) ASp oligonucleotide and
corresponding mutants.
elements in the promoter of the gene (Chen and Rothenberg, of Sp1 binding sites (Fig 1). Both clusters can potentially bind
factors related to AP-2 and Sp1. As shown in binding experiments,1994; Karlen et al, 1996).
MCAM mRNA synthesis in forskolin-treated SB2 cells was Sp1 was found to be associated with both the ASp and SCA
elements. Jean et al (1998a) recently demonstrated that upregulationsignificantly reduced in the presence of SCF and PMA. This
downregulatory effect was markedly attenuated by GF109203X, a of MCAM expression in highly metastatic cells correlates with loss
of expression of AP-2. Accordingly, we did not find any evidencespecific inhibitor of PCK. As elegantly demonstrated by
Blume-Jensen et al (1993, 1995), PKC can modulate the cellular of AP-2 binding on neither the ASp box or the SCA element in
SK-Mel2 cells, implying that Sp1 is necessary and sufficient toresponse to SCF, indicating that SCF and phorbol esters may
impede MCAM expression through a common PKC-dependent initiate MCAM transcription in metastatic cells. Surprisingly, we
could not demonstrate AP-2 binding to the ASp and SCA elementsregulatory pathway. The majority of cell lines established from
human melanomas do not express detectable levels of c-Kit mRNA in SB2 cells even though AP-2 binding activities were present in
the extracts (data not shown).or protein (Lassam and Bickford, 1992), making them insensitive
to SCF stimulation. As SCF is produced by keratinocytes and other The level of MCAM produced in SB2 cells could, however, still
be dramatically increased in forskolin-treated cells, indicating thatdermal cells in the skin (Longley et al, 1993), the loss of c-Kit
receptor may allow MCAM expression to take place in malignant additional regulatory factors might be required for full activation
of the gene. The cAMP-responsive transcription factor CREB hasmelanomas, hence contributing to tumor growth and eventually
metastasis. been shown to be a potent mediator of tumor growth and metastasis
of human melanoma cells, acting probably as a survival factor (JeanDeletion analysis indicated that the first 196 bp of the proximal
control region were still sufficient to get full promoter activity in et al, 1998b). In addition, MCAM synthesis was downregulated in
melanoma cells transfected with a dominant negative CREB mutantSK-Mel2 cells or in forskolin-treated SB2 cells. This fragment is
characterized by the presence of two clusters of regulatory elements, (Xie et al, 1997b). Sequence analysis of the MCAM gene reveals
the presence of a potential CRE binding element associated withthe ASp box and the SCA box, respectively, separated by a series
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Figure 9. Binding to the SCA element. DNA
mobility shift experiments were performed with a
35-mer oligonucleotide (nt –12 to –46) covering the
MCAM promoter region and containing the SCA
box and extracts from SK-Mel2 cells. (A) Formation
of two complexes (C1 and C2). The probe was
incubated either alone (probe) or in the presence of
SK-mel2 extracts derived either from unstimulated
cells (SK2) or from forskolin-treated cells (SK2 1 F).
Nuclear extracts from unstimulated cells were used
in competition experiments in which a 25- and a
125-fold molar excess of unlabeled oligonucleotides
was added prior binding. (B) C1 contains Sp1 and
C2 is specific for the SCA probe. Competition
experiments using the SCA probe were carried out
with extracts from unstimulated SK-Mel2 cells and a
125-fold molar excess of homologous (SCA) or
mutated (mut1 to mut7) SCA unlabeled
oligonucleotide. (C) The SCA probe and the
corresponding mutants.
the SCA box. We did not find any evidence of binding of CREB/
ATF factors to the SCA element, however, even though CREB/ We thank Dr. Willy Hofstetter and Dr. Robert R. Friis for critical reading of the
ATF proteins were found to interact with a consensus CRE motif manuscript. Mrs. B. Rohrbach provided excellent technical assistance. We are most
in both SK-Mel2 and forskolin-stimulated SB2 cells (data not grateful to Dr. B. Giovanella and Dr. M. Herlyn for providing the SB melanoma
shown). Moreover, upon deletion of the CRE motif, the MCAM cell lines and to Dr. K. Satyamoorthy for his invaluable advice on melanoma cell
promoter still responded to forskolin. The strong response of the culture. These investigations were supported by a grant from the Bernese Cancer
MCAM gene to cAMP induction might be explained by a second League to S.K.
CRE motif found at position 11126 in the first intron of the gene
(Sers et al, 1993). This CRE element is missing in the CAT
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